Spravato

WHoC is now certified to provide SPRAVATO®, a nasal spray approved for use, in conjunction with an oral antidepressant, in adults with treatment-resistant depression or depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®

.

SPRAVATO® is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO® as an anesthetic agent have not been established.

Because of the risks of sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors, SPRAVATO® carries a Boxed WARNING and is available only through a restricted distribution program called the SPRAVATO® REMS (Risk Evaluation and Mitigation Strategy). SPRAVATO® can be administered only by a healthcare

provider in a healthcare setting certified in the SPRAVATO® REMS program and to patients enrolled in the program.

SPRAVATO® is never dispensed directly to a patient for home use.

The medical staff at our REMS-certified SPRAVATO® treatment center is trained to prescribe, dispense, and administer SPRAVATO®. In addition, our care team educates patients on what to expect during their treatment with SPRAVATO® and investigates patients' benefits to ensure that you and your patients are aware of coverage and costs prior to SPRAVATO® treatment.

At WHoC, we understand that finding an appropriate treatment option for these patients can be complex. We are committed to partnering with your practice to provide a well-coordinated treatment experience with SPRAVATO® for appropriate adult patients. Our care team proactively coordinates care and ensures an open line of communication with referring providers to monitor their patients’ progress.

Indications:

SPRAVATO® (esketamine) CIII Nasal Spray is indicated, in conjunction with an oral antidepressant, for the treatment of:

• Treatment-resistant depression (TRD) in adults.

• Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

Limitations of Use:

The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®.

Testimonials